News & Updates
Filter by Specialty:
COSMIC-313 highlights benefit of triplet regimen in RCC
15 Sep 2023
byAudrey Abella
In the COSMIC-313 trial, the addition of the tyrosine kinase inhibitor (TKI) cabozantinib to the immune checkpoint inhibitor (ICI)-doublet regimen comprising nivolumab and ipilimumab (NIVO/IPI) improved progression-free survival (PFS) in patients with previously untreated, advanced renal-cell carcinoma (RCC) who had intermediate or poor prognostic risk according to the IMDC* category.
COSMIC-313 highlights benefit of triplet regimen in RCC
15 Sep 2023Stage IIIA/B NSCLC: Perioperative nivolumab plus chemo improves pCR, survival vs neoadjuvant chemo
15 Sep 2023
bySarah Cheung
Perioperative nivolumab plus platinum-based chemotherapy improves pathological complete response (pCR) rate and survival outcomes vs neoadjuvant platinum-based chemotherapy alone in patients with resectable stage IIIA/B non-small-cell lung cancer (NSCLC), results of the NADIM II trial have shown.